imdevimab

Indications

• treatment of outpatients with COVID-19 >= 14 years of age >= 40 kg
  • especially adults >= 65 years with COVID-19 at risk for severe disease
• prevention of COVID-19 in people with high-risk exposures
• casirivimab + imdevimab appears to be effective against B.1.351 variant from South Africa

* must be administered in combination with casirivimab

Contraindications

• not authorized hospitalized patients or patients who require oxygen therapy for COVID-19

* may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation

Dosage

• 1200 mg or 4000 mg once by intravenous infusion

Mechanism of action

• monoclonal antibody specifically directed against the spike protein of SARS-CoV2

More general terms

• monoclonal antibody to spike glycoprotein of SARS-CoV2 (COVID-19)

Component of

• casirivimab/imdevimab (REGEN-COV)